Literature DB >> 10508485

pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.

K Kobayashi1, B Bouscarel, Y Matsuzaki, S Ceryak, S Kudoh, H Fromm.   

Abstract

Irinotecan (CPT-11) and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), are believed to be reabsorbed by intestinal cells and to enter the entero-hepatic circulation, but there is little information to date. Our objective was to investigate the intestinal transport of CPT-11 and SN-38 in correlation with their associated cytotoxicity. Using either isolated hamster intestinal epithelial cells or/and human colon carcinoma HT29 cells, the uptake rates of [(14)C]CPT-11 and [(14)C]SN-38, both as respective non-ionic lactone form at acidic pH and anionic carboxylate form at basic pH, were investigated by the rapid vacuum filtration technique. The effect of physiologic intestinal luminal pH (6.2-8.0) on the uptake rate and cytotoxicity of SN-38 were estimated by the above method and the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, respectively. The lactone forms of CPT-11 and SN-38 were transported passively, while the respective carboxylate form was absorbed actively. Uptake rates of both lactones were significantly higher than those of their carboxylates. Under physiologic pH, the respective uptake rates of CPT-11 and SN-38 were pH sensitive and decreased significantly by around 65%, at pH greater than 6.8. Furthermore, with decreasing pH, a higher uptake rate of SN-38 into HT29 cells correlates with a greater cytotoxic effect (r = 0.987). CPT-11 and SN-38 have absorption characteristics of weakly basic drugs such as short-chain fatty acids, suggesting that alkalization of the intestinal lumen may be critical to reduce their reabsorption and associated side effects. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508485     DOI: 10.1002/(sici)1097-0215(19991112)83:4<491::aid-ijc10>3.0.co;2-m

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.

Authors:  Ji-Youn Han; Dae Ho Lee; Sung Young Lee; Chun Gun Park; Hae Young Kim; Eun-A Kim; Sung Min Yoon; Hong Gi Lee; Jin Soo Lee
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.

Authors:  Vicente Valentí Moreno; Joan Brunet Vidal; Hermini Manzano Alemany; Antonia Salud Salvia; Montserrat Llobera Serentill; Inés Cabezas Montero; Sonia Servitja Tormo; Eugenia Sopena Bert; Josep Gumà Padró
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

3.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

4.  Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids.

Authors:  Xin Liu; Amanda B Hummon
Journal:  J Am Soc Mass Spectrom       Date:  2015-01-21       Impact factor: 3.109

Review 5.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

6.  Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery.

Authors:  Jie Liu; Zhaozhong Jiang; Shengmin Zhang; W Mark Saltzman
Journal:  Biomaterials       Date:  2009-07-25       Impact factor: 12.479

7.  Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

Authors:  Kazuhiko Arimori; Noriaki Kuroki; Muneaki Hidaka; Tomomi Iwakiri; Keishi Yamsaki; Manabu Okumura; Hiroshige Ono; Norito Takamura; Masahiko Kikuchi; Masahiro Nakano
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

8.  A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

Authors:  Annabelle Ballesta; Sandrine Dulong; Chadi Abbara; Boris Cohen; Alper Okyar; Jean Clairambault; Francis Levi
Journal:  PLoS Comput Biol       Date:  2011-09-08       Impact factor: 4.475

9.  A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.

Authors:  Y Takeda; E Tsuduki; S Izumi; M Hojo; M Kamimura; G Naka; K Kobayashi; K Kudo
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

10.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Authors:  H Wildiers; G Guetens; G De Boeck; E Verbeken; B Landuyt; W Landuyt; E A de Bruijn; A T van Oosterom
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.